Rain Therapeutics trading resumes
PremiumThe FlyRain Therapeutics trading resumes
9M ago
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
Premium
Press Releases
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
9M ago
Rain Oncology to be Acquired by Pathos AI for $1.16 in cash per share
Premium
The Fly
Rain Oncology to be Acquired by Pathos AI for $1.16 in cash per share
9M ago
Rain Oncology confirms receipt of unsolicited proposal from Concentra
PremiumThe FlyRain Oncology confirms receipt of unsolicited proposal from Concentra
11M ago
Rain Oncology price target lowered to $1 from $1.50 at Citi
Premium
The Fly
Rain Oncology price target lowered to $1 from $1.50 at Citi
1y ago
Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Premium
Press Releases
Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100